ISB News

Ranish Lab Receives $156K Grant

Jeff Ranish

Jeff Ranish is an assistant professor at ISB. His expertise includes proteomics, macromolecular complexes and transcriptional regulation.

Congratulations to ISB faculty member Jeff Ranish and his group on receiving a new grant for $156,000. The award is for collaborative work with Peter Myler at Seattle BioMed on “Base J and transcription termination in Leishmania.”

Here’s the public health relevance statement from the proposal:

Human infections with the various species of Leishmania parasite cause substantial morbidity and mortality in tropical and sub-tropical countries world-wide. These organisms appear to differ from their animal hosts in the way that they transcribe the genetic information in their genomic DNA into messenger RNAs, which are used to make the proteins. These studies are designed to elucidate parasite-specific differences in this vital process, which we hope may be exploited for the development of novel anti-Leishmania drugs.

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.